---
document_datetime: 2023-09-21 18:16:33
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/repso-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: repso-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.195949
conversion_datetime: 2025-12-23 23:45:27.049024
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Repso

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended no   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                       |
|----------------------|---------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0020              | A.7 - Administrative change - Deletion of manufacturing sites | 30/03/2016 product                  |                                             | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                               |
| R/0018               | Renewal of the marketing authorisation. Medicinal             | 19/11/2015                          | 18/01/2016                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considered that the benefit-risk balance of Repso in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited |

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet).

The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                       | validity.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------|
| IAIN/0019 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/08/2015 | 18/01/2016 | SmPC and PL           |             |
| IA/0017/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites Medicinal product | 01/07/2015 | n/a no     | longer                | authorised  |
| IB/0016/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/04/2015 | 18/01/2016 | SmPC, Annex II and PL |             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal   | product    | no longer   | authorised             |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|------------------------|
| T/0014 | Transfer of Marketing Authorisation from Teva Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/10/2014 | 07/11/2014  | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| IB/0013            | To update sections 4.4 and 4.8 of the SmPC in order to add a warning and update the safety information on DRESS (drug reaction with eosinophilia and systemic symptoms). The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to update to the latest QRD template version and to update the contact details for the local representatives in IS, CY, LV, LU, HU, MT. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 11/07/2014         | 07/11/2014    | SmPC, Annex II and PL   | authorised                        |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-------------------------|-----------------------------------|
| PSUSA/1837/ 201309 | Periodic Safety Update EU Single assessment - LEFLUNOMIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/04/2014         | n/a no longer |                         | PRAC Recommendation - maintenance |
| N/0012             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 15/01/2014 product | 06/02/2014    | PL                      |                                   |
| IAIN/0010          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/06/2013         | n/a           |                         |                                   |
| IB/0009            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Medicinal                                                                                                                                                                                                                                                                                                                                                                                                               | 28/01/2013         | 06/02/2014    | SmPC and PL             |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0008/G   | This was an application for a group of variations.                                                                                                                                                                                                       | 29/11/2012         | n/a           |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0007     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH           | 11/06/2012         | 29/10/2012 no | SmPC, Annex II, Labelling and PL longer | Implementation of changes approved in the reference product - update of section 4.4 to add a warning for peripheral neuropathy and the frequency of this event has been changed to 'commom' in section 4.8 as requested by CHMP. The PIL has been updated accordingly. Further updates concern the implementation of the latest QRD template. In addition, the MAH updated the list of local representatives for Austria, Germany, Finland, Ireland, Malta and Norway. authorised |
| IB/0006     | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                | 19/04/2012 product | n/a           |                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0005     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Medicinal | 05/12/2011         | 06/03/2012    | SmPC and Labelling                      | Update of section 4.4 of the SmPC regarding the risk of leflunomide use in combination with biologicals following the CHMP assessment of the COLEBI study (FU2 038.1) as implemented in the originator product Arava II-49. The MAH also took the opportunity to update sections 8 and 9 of the SmPC and section 12 in the labelling with the EU numbers and the date of authorisation.                                                                                           |

<div style=\"page-break-after: always\"></div>

| IA/0004   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                      | 26/09/2011         | n/a                    |                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0003   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                               | 06/09/2011         | n/a SmPC               | Update of sections 4.2 and 5.1 of the SmPC to reflect the outcome of the clinical study R01143 (LEADER) regarding the use of a loading dose, as requested by CHMP. authorised                                                                                                                                                                                                                |
| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                               | 04/08/2011         | n/a SmPC, II no longer | Annex and PL Implementation of changes approved in reference product - update of section 4.4 to amend the warning for interstitial lung disease (ILD) as requested by CHMP. The PIL was revised accordingly. In addition the description of the risk of teratogenicity in the PIL was strengthened. Further updates concern the Annex IIB and the implementation of the latest QRD template. |
| IB/0001/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to batch release arrangements Medicinal | 08/06/2011 product | n/a                    |                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place   |
|---------------------------------------------------------------------------------------------------------------------|

<!-- image -->